Close Menu

NEW YORK (360Dx) – Owlstone Medical today announced that it has completed a $50 million financing round to support the development and commercialization of a breath biopsy platform for early disease detection.

The funding includes a previously announced round valued at $15 million and brings the total raised by Cambridge, UK-based Owlstone to about $73 million since its founding in 2016.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.